Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
MENRIUM 5-4 is an oral tablet formulation approved by Roche in 1966 for management of menopausal symptoms and related anxiety. The product represents a legacy small-molecule therapeutic from the mid-20th century with mechanism of action related to anxiolytic/sedative properties. It was designed to address vasomotor symptoms and emotional disturbances associated with menopause.
Product is in advanced lifecycle stage with low current commercial momentum; minimal team growth expected as portfolio focus shifts to newer assets.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on MENRIUM 5-4 offers limited career growth opportunity given LOE-approaching lifecycle and zero linked job openings. Roles focus on managed decline, reimbursement defense, and patient access rather than expansion or innovation. This assignment suits professionals managing legacy assets or seeking stability over advancement.
Worked on MENRIUM 5-4 at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.